Health Press Release – Newsletter for December 2, 2010

SEEK: PepTcell Changes Name due to New Focus and Success

LONDON, December 1, 2010 – PepTcell, a leading UK privately-owned drug-discovery group, today
announced it is changing its name to SEEK.

Gregory Stoloff, Chief Executive Officer, explains: "SEEK has
a significant number of potential blockbuster assets in different legal
entities and we wanted to give them a common identity and purpose. Announcing
a simple and …. Source article  : SEEK: PepTcell Changes Name due to New Focus and Success.

Shire Reports Positive Efficacy and Safety Results From FAST-3 Study of FIRAZYR(R) (icatibant) for Acute Attacks of Hereditary Angioedema

DUBLIN, December 1, 2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, today announced topline results from FAST-3 (For
Angioedema Subcutaneous Treatment), the largest of the Phase III trials
studying the use of FIRAZYR(R) (icatibant) for treatment of acute attacks of
hereditary angioedema (HAE).

The study showed that patients receiving treatment …. Read the original article  : here.

Elsevier Launches Innovative Online Radiology Board Review Product

New Case Reviews Online Series Mimics Format of Board Exams and Offers Interactive Self-Assessment Environment for Radiology Professionals

PHILADELPHIA, December 1, 2010 – Elsevier (www.elsevier.com/), the leading publisher of scientific,
technical and medical information products and services, today announced the
availability of Case Reviews Online, an online edition of Case Reviews print
series offering radiology professionals self-assessment preparation … Read more »».

Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillation

More Than 21,000 Patients Enrolled in the Largest Clinical Study With a Factor Xa Inhibitor

LONDON, December 1, 2010 – Daiichi Sankyo Company, Limited (TSE: 4568), announced today that it has
successfully completed patient enrollment for its phase III ENGAGE AF-TIMI 48
clinical study of edoxaban, a direct, specific, oral Factor Xa inhibitor that
is being investigated in … Read : Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillation.

Experts Emphasize That Beta-Carotene is Indispensable as a Safe Source of Vitamin A

JENA, Germany, December 1, 2010 – The intake of preformed vitamin A from animal products is not
sufficient in parts of the population in Europe, the U.S. and Asia. The
vitamin A precursor beta-carotene therefore has an important function in
providing for an adequate supply of total vitamin A, international carotenoid
experts state in a recently published consensus …. Source article on Gaea Times at  : Experts Emphasize That Beta-Carotene is Indispensable as a Safe Source of Vitamin A.

Janssen Pharmaceutica N.V. Announces Collaboration to Develop Diagnostic Biosignatures for Pre-Symptomatic Identification of Alzheimer’s Disease

BEERSE, Belgium, December 1, 2010 – Janssen Pharmaceutica N.V., (Janssen) today announced a research
agreement to collaborate with GE Healthcare to develop non-invasive or
minimally invasive diagnostic biosignatures to detect Alzheimer's disease
prior to the onset of clinical symptoms. Pre-symptomatic biosignatures will
allow earlier diagnosis of the disease and may enable significantly earlier
intervention in Alzheimer's disease.

… Read the original article on Gaea Times at : Janssen Pharmaceutica N.V. Announces Collaboration to Develop Diagnostic Biosignatures for Pre-Symptomatic Identification of Alzheimer's Disease.

Update: Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillation

More Than 21,000 Patients Enrolled in the Largest Clinical Study with a Factor Xa Inhibitor

TOKYO, December 1, 2010 – Daiichi Sankyo Company, Limited (TSE: 4568), announced today
that it has successfully completed patient enrollment for its phase III
ENGAGE AF-TIMI 48 clinical study of edoxaban, a direct, specific, oral Factor
Xa inhibitor that is being investigated in … Read : Update: Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillation.